Utilization of Ocrelizumab within Different Treatment Strategies for Multiple Sclerosis: A 5-Year Population-Based Study.

Marcello Moccia Giuseppina AffinitoGiuseppina MarrazzoCecilia PolitiPaolo Di ProcoloLicia ConfalonieriAntonio CarotenutoMaria PetraccaRoberta LanzilloMaria TriassiVincenzo Brescia MorraRaffaele Palladino

Published in: Neurology international (2024)

From 2018 to 2022, ocrelizumab was among the most frequently prescribed DMTs, with 28.8% prescriptions to incident MS patients, confirming its relevance in clinical practice. Ocrelizumab was associated with the highest persistence and adherence, pointing towards its favorable benefit-risk profile. The costs of ocrelizumab were lower than those of other highly active DMTs.

Keyphrases

multiple sclerosis
clinical practice
end stage renal disease
newly diagnosed
ejection fraction
mass spectrometry
cardiovascular disease
prognostic factors
peritoneal dialysis
type diabetes
patient reported outcomes
adipose tissue